Search Results
Sep 03, 2026, 19:10 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron stock dropped nearly 10%, according to the complaint.THE LEAD PLAINTIFF PROCESS: The Private Securities
More news about: Robbins Geller Rudman & Dowd LLP
Sep 03, 2026, 15:15 ET REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Sep 03, 2026, 11:58 ET LAKE VICTORIA GOLD COMPLETES INITIAL ACCESS ROAD REPAIRS AND ADVANCES SITE EARTHWORKS AT IMWELO GOLD PROJECT
surrounding communities."Cautionary Note on Production DecisionAlthough Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Lake Victoria Gold Ltd.
Sep 03, 2026, 10:07 ET REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt
altered to expand the patient population eligible for PFS analysis.A second market reaction followed Regeneron's May 15, 2026 announcement that the Phase 3 trial did not reach statistical significance for the primary endpoint of improvement in PFS. The lawsuit asserts that these disclosures corrected
More news about: SueWallSt.com
Sep 03, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
[95% CI, 67.25–79.97] vs. 45.7% [95% CI, 38.59–52.91]; P<0.0001).2Significantly improved PFS with etentamig vs. SAT (HR, 0.40; 95% CI, 0.29–0.54; P<0.0001). The PFS benefit was observed across all pre-specified subgroups evaluated.212-month overall survival
More news about: AbbVie
Sep 03, 2026, 09:08 ET Gold Forecast to Reach $4,900 an Ounce as Central Bank Buying Holds
of shares outstanding.There are several risks associated with the Company's plans. Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, but those foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo establishing
More news about: American News Group
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
2024, at a prespecified interim analysis conducted by the IDMC, ivonescimab met its primary endpoint of progression-free survival (PFS) in the HARMONi-2 study, with a median PFS of 11.14 months versus 5.82 months for pembrolizumab. HARMONi-2 is the first randomized, double-blind Phase III trial to show a
More news about: Akeso, Inc.
Sep 01, 2026, 12:21 ET INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Sep 01, 2026, 09:00 ET Allworth Financial Surpasses $40B AUM with Acquisitions in Rochester, N.Y., and Indianapolis
including two private funds, that expand capabilities across Allworth's national platform.Holistic Financial Partners, led by Jason Llewellyn, CPA, PFS, CDFA, adds dedicated divorce financial planning capabilities to Allworth's national platform. Llewellyn, who joins Allworth as a Partner Advisor, is
More news about: Allworth Financial
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
ORR of 100.0% (11/11) and DCR of 100.0% (11/11) in patients treated at 30 mg/kg. After median follow up of 6 months, median progression-free survival (PFS) and DOR have not been reached.Second-line or later NSCLC monotherapy (30 mg/kg): ORR of 28.0% (7/25) and DCR of 60.0% (15/25), with a 6-month
More news about: CStone Pharmaceuticals
Aug 31, 2026, 08:00 ET T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
actively pursued. In July 2026, Hansoh Pharmaceutical announced that its B7-H3 ADC, HS-20093, met the primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC) in patients with relapsed or progressive osteosarcoma in the pivotal Phase III ARTEMIS-011 study.
More news about: T-MAXIMUM PHARMACEUTICAL
Aug 31, 2026, 07:00 ET Defense Metals Resource Upgrade Drilling Intersects 2.86% TREO over 65 Metres; Including 6.15% TREO over 20 Metres at the Wicheeda Rare Earth Project
detailed in the Company's 2025 Preliminary Feasibility Study ("PFS"; refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS shows the economic potential of the deposit and supports
More news about: Defense Metals Corp.
Aug 31, 2026, 07:00 ET BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
chemotherapy (gemcitabine and nab-paclitaxel).A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.APHEXDA Performance UpdateFor
More news about: BioLineRx Ltd.
Aug 31, 2026, 06:00 ET Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
chemotherapy and tislelizumab; zanidatamab in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial evaluated dual primary endpoints, PFS per blinded independent central review (BICR) and OS.About Gastroesophageal AdenocarcinomaGEA, including cancers of the stomach,
More news about: Jazz Pharmaceuticals plc
Aug 28, 2026, 12:06 ET Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 28, 2026, 07:00 ET InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
the combination group.Progression-Free Survival (PFS): In the single-arm study, the median PFS was 6.9 months (95% CI: 2.8–12.0). In the randomized study, ifebemtinib plus garsorasib achieved a median PFS of 7.7 months (95% CI: 3.0–NE) versus 4.0 months (95% CI: 2.0–5.6) with
More news about: InxMed Co., Ltd
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
first-line treatment of sq-NSCLC. Based on the HARMONi-6 study, this is the first regimen to achieve dual positive OS and progression-free survival (PFS) results versus a PD-1 monoclonal antibody plus chemotherapy in a randomized, double-blind Phase III trial. Ivonescimab combination therapy marks a significant
More news about: Akeso, Inc.
Aug 27, 2026, 16:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
ORR of 100.0% (11/11) and DCR of 100.0% (11/11) in patients treated at 30 mg/kg. After median follow up of 6 months, median progression-free survival (PFS) and DOR have not been reached.Second-line or later NSCLC monotherapy (30 mg/kg): ORR of 28.0% (7/25) and DCR of 60.0% (15/25), with a 6-month
More news about: CStone Pharmaceuticals
Aug 27, 2026, 10:09 ET REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
April 29, 2026 protocol changes expanding patients eligible for PFS analysis as a key event that raised investor concerns.The May 15, 2026 announcement stated the Phase 3 trial did not reach statistical significance for its primary PFS endpoint.Why Accountability Allegations Matter
More news about: SueWallSt.com
Aug 27, 2026, 09:00 ET The World's Gold Mines Are Draining Faster Than New Ones Get Built; The Market Is Rewarding Whoever Can Pour First
representative and can exhibit short-range variability; and individual assays are not indicative of average grades. The Imwelo Gold Project's prior PEA, PFS and updated PFS work was completed under the JORC Code and is not current under National Instrument 43-101; the company has not completed a feasibility study
More news about: American News Group
Aug 27, 2026, 07:00 ET LAKE VICTORIA GOLD INTERSECTS 28.71 G/T AU OVER 2.75 M AND 12.20 G/T AU OVER 4.50 M IN SHALLOW AREA C DRILLING AT IMWELO
Cautionary Note on Production DecisionAlthough Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Lake Victoria Gold Ltd.
Aug 26, 2026, 18:14 ET Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 26, 2026, 10:07 ET REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
rate.Phase I pooled median PFS was cited as approximately 24 months.Management allegedly suggested low-to-mid-teens median PFS could be practice changing.The complaint alleges the trial later required expanded patient criteria for PFS analysis.On May
More news about: Levi & Korsinsky, LLP